Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has received official minutes from a Type C meeting with the U.S. Food and Drug Administration (FDA) that support the company's plans for an adaptive Phase 2 field study of TNX-4800, its investigational long-acting anti-OspA monoclonal antibody designed to prevent Lyme disease. The announcement, made via press release, marks a significant step forward in the development of a potential seasonal immunopreventative for a disease that affects hundreds of thousands of Americans annually.
The planned randomized, placebo-controlled study is expected to enroll approximately 3,300 adults over two Lyme disease seasons. The trial will evaluate the efficacy of TNX-4800 in preventing Lyme disease through six months after dosing, with the goal of covering the entire U.S. Lyme disease season. Manufacturing of the investigational product is on track for delivery to study sites in the first quarter of 2027, according to the company.
TNX-4800 is being developed as a seasonal immunopreventative administered as two subcutaneous injections three months apart. If successful, it could provide a new tool in the fight against Lyme disease, which is transmitted by tick bites and can cause severe, long-lasting symptoms if not treated early. Current prevention methods focus on personal protective measures and tick control, with no vaccine currently available for humans in the U.S.
The FDA's feedback is crucial because it provides a regulatory pathway for the study design, which is adaptive in nature, allowing for modifications based on interim data. This flexibility could speed up the development process, bringing a potential preventative to market sooner. The study's large size and duration over two seasons will provide robust data on the drug's effectiveness and safety.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. The company's flagship medicine, TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), was recently approved for fibromyalgia, marking the first new treatment for the condition in over 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® SymTouch® and Tosymra®.
Beyond its CNS portfolio, Tonix is advancing a pipeline of immunology programs, including TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. The company's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.
The news of FDA support for the TNX-4800 study comes at a time when Lyme disease incidence is rising, with the CDC estimating approximately 476,000 cases per year in the U.S. A preventative that could be administered before the tick season would be a major public health advancement. The company's progress in this area is being closely watched by investors and public health officials alike.
For more information about Tonix Pharmaceuticals and its pipeline, visit the company's newsroom at https://ibn.fm/TNXP.
